These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38890511)

  • 1. Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID-19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial.
    Ohmagari N; Yotsuyanagi H; Doi Y; Yamato M; Imamura T; Sakaguchi H; Yamanaka H; Imaoka R; Fukushi A; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
    Influenza Other Respir Viruses; 2024 Jun; 18(6):e13338. PubMed ID: 38890511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.
    Yotsuyanagi H; Ohmagari N; Doi Y; Yamato M; Bac NH; Cha BK; Imamura T; Sonoyama T; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
    JAMA Netw Open; 2024 Feb; 7(2):e2354991. PubMed ID: 38335000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
    Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Fukuhara T; Ichihashi G; Sanaki T; Baba K; Takeda Y; Tsuge Y; Uehara T
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069722. PubMed ID: 36098519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.
    Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Sakaguchi H; Sonoyama T; Ichihashi G; Sanaki T; Baba K; Tsuge Y; Uehara T
    Clin Infect Dis; 2023 Apr; 76(8):1403-1411. PubMed ID: 36477182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial.
    Yotsuyanagi H; Ohmagari N; Doi Y; Yamato M; Fukushi A; Imamura T; Sakaguchi H; Sonoyama T; Sanaki T; Ichihashi G; Tsuge Y; Uehara T; Mukae H
    Antiviral Res; 2024 Sep; 229():105958. PubMed ID: 38972603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ensitrelvir in patients with SARS-CoV-2: A retrospective chart review.
    Yamato M; Kinoshita M; Miyazawa S; Seki M; Mizuno T; Sonoyama T
    J Infect Chemother; 2024 Sep; 30(9):946-950. PubMed ID: 38367932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological characteristics and clinical study results of ensitrelvir fumaric acid (XOCOVA
    Tsuge Y; Ariwa Y; Shibata K
    Nihon Yakurigaku Zasshi; 2024; 159(4):264-281. PubMed ID: 38945910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with ensitrelvir for COVID-19 in hospitalized patients of very advanced age: Case series.
    Tomita T; Miyazawa S; Sonoyama T
    Medicine (Baltimore); 2024 Jul; 103(30):e39080. PubMed ID: 39058834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
    Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
    Medicine (Baltimore); 2023 Feb; 102(8):e33024. PubMed ID: 36827007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sporadic Occurrence of Ensitrelvir-Resistant SARS-CoV-2, Japan.
    Doi A; Ota M; Saito M; Matsuyama S
    Emerg Infect Dis; 2024 Jun; 30(6):1289-1291. PubMed ID: 38669127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ito T
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0106424. PubMed ID: 39207153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
    Nobori H; Baba K; Kuroda T; Baba K; Matsumoto K; Yoshida S; Watari R; Tachibana Y; Kato T; Fukao K
    Antiviral Res; 2024 Apr; 224():105852. PubMed ID: 38428748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivermectin for preventing and treating COVID-19.
    Popp M; Reis S; Schießer S; Hausinger RI; Stegemann M; Metzendorf MI; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015017. PubMed ID: 35726131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.
    Cairns DM; Dulko D; Griffiths JK; Golan Y; Cohen T; Trinquart L; Price LL; Beaulac KR; Selker HP
    JAMA Netw Open; 2022 Feb; 5(2):e2144942. PubMed ID: 35138402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ensitrelvir Fumaric Acid: First Approval.
    Syed YY
    Drugs; 2024 Jun; 84(6):721-728. PubMed ID: 38795314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.